None
DE
uniQure (NASDAQ:QURE) Issues Quarterly Earnings Results, Misses Expectations By $0.40 EPS
['Logan Wallace']
Ticker Report
Following the completion of the sale, the director directly owned 43,254 shares of the company’s stock, valued at $1,949,025.24.
Following the completion of the transaction, the director owned 25,996 shares of the company’s stock, valued at $1,207,254.24.
Insiders sold 433,229 shares of company stock valued at $17,944,799 over the last ninety days.
California State Teachers Retirement System purchased a new stake in shares of uniQure in the second quarter valued at $540,000.
uniQure Company Profile(Get Free Report)uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs.